RT Journal Article
SR Electronic
T1 Prognostic value of FDG PET/CT before palliative chemotherapy in metastatic gastric carcinoma
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1768
OP 1768
VO 50
IS supplement 2
A1 Chung, Hyun Woo
A1 Cho, Yo-Han
A1 Yoon, So Young
A1 Lee, Mark Hong
YR 2009
UL http://jnm.snmjournals.org/content/50/supplement_2/1768.abstract
AB 1768 Objectives We evaluated the role of FDG PET/CT in metastatic gastric carcinoma in terms of chemo-responsiveness and survival. Methods This study included 30 newly diagnosed metastatic gastric carcinoma patients (M:F = 21:9, 57 ± 14 yr) who underwent FDG PET/CT before the palliative chemotherapy between 2006 and 2008. The SUVmax of primary and metastatic sites were assessed. Survival analysis was performed using the Kaplan-Meier method. Cox proportional hazard models were used to determine independent risk factors. Results The histology of gastric carcinoma was 28 adenocarcinoma and 2 signet ring cell carcinoma. The mean SUVmax of primary, metastatic, and overall sites were 8.2 ± 4.7, 8.8 ± 4.6, and 9.9 ± 5.0, respectively. Among 25 evaluable patients, 15 showed partial response (PR), 6 stable disease (SD), and 4 progressive disease (PD) after chemotheraphy. Mean SUVmax of primary site was significantly different between PD and SD (9.3 ± 1.9 vs. 5.7 ± 1.4; P=0.01). High SUVmax of overall sites (cut-off value 9, P=0.004), presence of heptatic meteastasis (P=0.047), and more than 2 metastatic sites (P=0.048) were significant univariate predictors for OS. Multivariate analysis showed only high SUVmax of overall sites was independently associated with OS with marginal significance (P=0.053). Conclusions Assessment of FDG uptake in patients with metastatic gastric carcinoma may provide useful information regarding chemo-responsiveness and overall survival.